Westover Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.82M Sell
5,727
-166
-3% -$90.1K 0.52% 45
2025
Q4
$3.41M Sell
5,893
-114
-2% -$64.5K 0.62% 38
2025
Q3
$2.91M Sell
6,007
-58
-1% -$27K 0.54% 45
2025
Q2
$2.46M Sell
6,065
-3,446
-36% -$1.44M 0.49% 49
2025
Q1
$4.73M Sell
9,511
-186
-2% -$101K 1.05% 21
2024
Q4
$5.04M Sell
9,697
-109
-1% -$59.9K 1.11% 20
2024
Q3
$6.07M Buy
9,806
+912
+10% +$540K 1.17% 20
2024
Q2
$4.92M Sell
8,894
-7
-0.1% -$4.01K 1.27% 19
2024
Q1
$5.17M Sell
8,901
-204
-2% -$114K 1.51% 18
2023
Q4
$4.83M Sell
9,105
-124
-1% -$60K 1.57% 16
2023
Q3
$4.67M Sell
9,229
-431
-4% -$230K 1.69% 13
2023
Q2
$5.04M Sell
9,660
-470
-5% -$254K 1.75% 11
2023
Q1
$5.84M Sell
10,130
-15
-0.1% -$8.45K 2.16% 9
2022
Q4
$5.59M Sell
10,145
-885
-8% -$469K 2.21% 8
2022
Q3
$5.59M Sell
11,030
-100
-0.9% -$56K 2.14% 9
2022
Q2
$6.05M Sell
11,130
-795
-7% -$438K 2.23% 9
2022
Q1
$7.04M Sell
11,925
-444
-4% -$255K 2.2% 9
2021
Q4
$8.25M Sell
12,369
-1,312
-10% -$819K 2.4% 7
2021
Q3
$7.82M Sell
13,681
-22
-0.2% -$12.1K 2.45% 7
2021
Q2
$6.91M Sell
13,703
-270
-2% -$127K 2.22% 9
2021
Q1
$6.38M Sell
13,973
-1,291
-8% -$616K 2.19% 10
2020
Q4
$7.11M Sell
15,264
-1,103
-7% -$517K 2.56% 7
2020
Q3
$7.23M Sell
16,367
-572
-3% -$236K 2.97% 7
2020
Q2
$6.14M Sell
16,939
-992
-6% -$333K 2.88% 7
2020
Q1
$5.08M Sell
17,931
-463
-3% -$146K 2.75% 9
2019
Q4
$5.98M Sell
18,394
-2,798
-13% -$848K 2.67% 7
2019
Q3
$6.17M Sell
21,192
-598
-3% -$171K 2.92% 4
2019
Q2
$6.4M Buy
21,790
+298
+1% +$82.1K 3.16% 4
2019
Q1
$5.88M Sell
21,492
-393
-2% -$97.8K 3.06% 4
2018
Q4
$4.9M Sell
21,885
-1,007
-4% -$236K 3.07% 4
2018
Q3
$5.59M Sell
22,892
-1,247
-5% -$287K 2.83% 3
2018
Q2
$5M Sell
24,139
-1,329
-5% -$282K 2.69% 3
2018
Q1
$5.26M Buy
25,468
+1,959
+8% +$411K 2.86% 3
2017
Q4
$4.46M Buy
23,509
+839
+4% +$161K 2.45% 4
2017
Q3
$4.29M Buy
22,670
+608
+3% +$110K 2.52% 8
2017
Q2
$3.85M Sell
22,062
-976
-4% -$164K 2.53% 7
2017
Q1
$3.54M Sell
23,038
-1,739
-7% -$266K 2.36% 10
2016
Q4
$3.5M Buy
24,777
+2,223
+10% +$328K 2.5% 9
2016
Q3
$3.59M Buy
22,554
+2,024
+10% +$312K 2.66% 8
2016
Q2
$3.03M Buy
20,530
+3,880
+23% +$573K 2.49% 16
2016
Q1
$2.36M Sell
16,650
-574
-3% -$76.9K 1.99% 16
2015
Q4
$2.44M Sell
17,224
-130
-0.7% -$17.3K 2.04% 17
2015
Q3
$2.12M Buy
17,354
+314
+2% +$40.9K 1.83% 20
2015
Q2
$2.21M Buy
17,040
+17
+0.1% +$2.22K 1.76% 21
2015
Q1
$2.29M Buy
17,023
+403
+2% +$52K 1.85% 18
2014
Q4
$2.08M Sell
16,620
-1,044
-6% -$127K 1.78% 21
2014
Q3
$2.15M Buy
17,664
+1,989
+13% +$242K 1.75% 22
2014
Q2
$1.85M Sell
15,675
-2,545
-14% -$300K 1.56% 23
2014
Q1
$2.19M Sell
18,220
-12,750
-41% -$1.52M 2.04% 19
2013
Q4
$3.45M Sell
30,970
-912
-3% -$90.7K 3.29% 6
2013
Q3
$2.94M Sell
31,882
-4,417
-12% -$399K 3.04% 5
2013
Q2
$3.07M Buy
+36,299
New +$3.02M 3.02% 4

Other funds holding TMO

Westover Capital Advisors's TMO Position: Q1 2026 in Review

Westover Capital Advisors reduced its Thermo Fisher Scientific (TMO) stake by 2.8% in Q1 2026, selling an estimated $90.1K and leaving 5,727 shares worth $2.82M. The position accounts for 0.52% of the portfolio, ranked #45.

Westover Capital Advisors first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.25M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Westover Capital Advisors held 5,727 shares of Thermo Fisher Scientific worth $2.82M as of Q1 2026.
  • Westover Capital Advisors sold 166 Thermo Fisher Scientific shares in Q1 2026, an estimated $90.1K.
  • Thermo Fisher Scientific made up 0.52% of Westover Capital Advisors's portfolio in Q1 2026, its #45 holding.
  • Westover Capital Advisors first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Westover Capital Advisors's Thermo Fisher Scientific position peaked at $8.25M in Q4 2021.
  • 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Westover Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.